IP Library Granted Patent US 12,337,020
Granted Patent B2
US 12,337,020 · App. 17/047,611 · Granted Jun 24, 2025

Bacteriophage compositions

Inventors: Markus Rast (Singen, DE); Sergio Rodriguez-Morillas (Basel, CN); Tomomine Iida (Osaka, JP)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LTD.
A61K35/76A61K9/1623A61K9/1652C12N2795/10132C12N2795/10232C12N2795/10332
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,337,020
App. No.
17/047,611
Granted
Jun 24, 2025
Kind
B2
Abstract

The present invention relates to a bacteriophage composition comprising at least one bacteriophage species, at least one α-linked polymeric glucose and at least one polyol. In certain embodiments, the α-linked polymeric glucose has a mean molecular weight of greater than 10 kDa.

Claims (31)

1. A bacteriophage composition comprising:

at least one bacteriophage species,

at least one α-linked polymeric glucose,

at least one polyol, wherein the polyol is sucrose or sorbitol,

and optionally other ingredients selected from the group of buffer salts, electrolytes and surfactants, and wherein the weight ratio of the α-linked polymeric glucose to the polyol is about 4:6 to 8:2.

2. The bacteriophage composition according to claim 1 , wherein the α-linked polymeric glucose has a mean molecular weight from about 10 kDa to 1000 kDa, or from about 30 kDa to about 1000 kDa, or from about 150 kDa to about 800 kDa.

3. The bacteriophage composition according to claim 1 in the form of a dry composition, wherein the water content is less than 10% w/w, or less than 8% w/w, or less than 5% w/w, or less than 4% w/w.

4. A dry bacteriophage composition according to claim 3 , obtainable by spray drying a liquid composition.

5. The bacteriophage composition according to claim 1 , wherein one or more of the bacteriophage species are selected from the group of Caudovirales.

6. The bacteriophage composition according to claim 1 , wherein the α-linked polymeric glucose is selected from the group of dextrans and starches.

7. The bacteriophage composition according to claim 6 , wherein the α-linked polymeric glucose is a modified starch.

8. The bacteriophage composition according to claim 6 , wherein the α-linked polymeric glucose is a dextran.

9. A method of treating a bacterial infection comprising

administering to an animal or human patient in need of such a treatment a unit dose of the dry bacteriophage composition according to claim 3 , or

administering to an animal or human patient in need of such a treatment a unit dose of a reconstituted liquid bacteriophage composition obtainable by reconstituting the dry composition according to claim 3 in a pharmaceutically acceptable liquid.

10. A method for stabilizing a bacteriophage species during spray drying, the method comprising spray drying a bacteriophage species in combination with an α-linked polymeric glucose with a mean molecular weight of from about 10 kDa to about 1000 kDa, and a polyol, wherein the polyol is sucrose or sorbitol, and wherein the weight ratio of the α-linked polymeric glucose to the polyol is about 4:6 to 8:2.

11. The method of claim 10 , wherein the α-linked polymeric glucose is a hydroxyethyl starch or a dextran.

12. A process of preparing a dried bacteriophage composition comprising at least step 1 and step 2, involving preparing in step 1 a composition in an evaporable liquid comprising:

at least one bacteriophage species,

at least one α-linked polymeric glucose,

at least one polyol, wherein the polyol is sucrose or sorbitol,

and optionally other ingredients selected from buffer salts, electrolytes and surfactants, wherein the weight ratio of the α-linked polymeric glucose to the polyol is about 4:6 to 8:2, and

spray drying said liquid composition from step 1 in step 2 to obtain a dry bacteriophage composition.

13. The process according to claim 12 , wherein the α-linked polymeric glucose has a mean molecular weight of from about 10 kDa to about 1000 kDa or from about 40 kDa to about 1000 kDa, or from about 150 kDa to about 1000 kDa.

14. The process of claim 12 , wherein the log loss of activity (pfu/g) of at least three bacteriophage species from the liquid composition in step 1 to the dried particles in step 2 is less than 2, or less than 1.5 or less than 1.1.

15. The bacteriophage composition according to claim 5 , wherein one or more of the bacteriophage species are selected from the subgroups of Myoviridae, Podoviridae, Siphoviridae or mixtures thereof.

16. The bacteriophage composition according to claim 7 , wherein the α-linked polymeric glucose is a hydroxyalkyl starch.

17. The bacteriophage composition according to claim 16 , wherein the α-linked polymeric glucose is a hydroxyethyl starch.

18. The method of claim 10 , wherein the α-linked polymeric glucose has a mean molecular weight of from about 40 kDa to about 1000 kDa.

19. The method of claim 10 , wherein the α-linked polymeric glucose has a mean molecular weight of from about 150 kDa to about 1000 kDa.

20. The bacteriophage composition according to claim 3 , wherein the composition maintains stable activity of the bacteriophage species during storage at 25° C. and 60% relative humidity over 1 month characterized by a log loss of activity of less than about 2 to less than about 0.5 pfu/g, over 3 months characterized by a log loss of activity of less than about 5 to less than about 0.8 pfu/g, or over 6 months characterized by a log loss of activity of less than about 5 to less than about 1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2023
From: IIDA, TOMOMINE
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 062722/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2023
From: RAST, MARKUS; RODRIGUEZ MORILLAS, SERGIO
To: TAKEDA GMBH
Reel/Frame 062722/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2021
From: TAKEDA GMBH
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 058154/0122 →
Priority Claims (1)
EP 18167994 · Apr 18, 2018 · regional
Continuity (1)
Related Publication 20210121510A1 · Apr 29, 2021
References Cited (20)
US 8012507B2 · Troung-Le et al. · 2011 [cited by applicant]
US 20080118468A1 · Sulakvelidze · 2008 [cited by examiner]
US 20090093041A1 · Walbeck · 2009 [cited by applicant]
CN 105950475A · 2016 [cited by applicant]
CN 107574155A · 2018 [cited by applicant]
JP 2006512102A · 2006 [cited by applicant]
WO 2016118738A1 · 2016 [cited by applicant]
Saboo, et al., “Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus”, Molecular Pharmaceutics, vol. 13, No. 5, May 2016. [cited by applicant]
Vandenheuvel, et al., “Feasibility of spray drying bacteriophages into respirable powsers to combat pulmonary bacterial infections”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 84, No. 3, Jan. 2013. [cited by applicant]
Malik, et al., “Formulation, stabilisation and encapsulation of bacteriophage for phage therapy”, Advances in Colloid and Interface Science, vol. 249, May 2017. [cited by applicant]
Bodier-Montagutelli, et al., “Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections”, Expert Opinion on a Drug Delivery, vol. 14, No. 8, Nov. 2016. [cited by applicant]
Merabishvili, et al., “Stability of [cited by applicant]
Leclair, et al., “Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying”, International Journal of Pharmaceutics, vol. 506, No. 1, Apr. 2016. [cited by applicant]
Leclair, et al., Optimization of Spray Drying Conditions for Yield, Particle Size and Biological Activity of Thermally Stable Viral Vectors, Pharmaceutical Research, vol. 33, No. 11, Jul. 2016. [cited by applicant]
Engel, et al., “The preservation of mycobacteriophages by means of freeze drying”, The American Review of Respiratory Disease, American Thoracic Society, vol. 109, No. 5, Apr. 1974. [cited by applicant]
Gonzalez-Menendez, et al., “Comparative analysis of different preservation techniques for the storage of [cited by applicant]
Anany, et al., Biocontrol of Listeria monocytogenes and [cited by applicant]
Tang, et al., “Whey protein improves survival and release characteristics of bacteriophage Felix 01 encapsulated in alginate microsphers”, Food Research International, vol. 52, No. 2, Dec. 2012. [cited by applicant]
Ma, et al., “Enhanced alginate microspheres as means of oral delivery of bacteriophage for reducing intestinal carriage”, Food Hydrocolloids, vol. 26, No. 2, Nov. 2010. [cited by applicant]
Leung, et al., “Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections”, Pharmaceutical Research, vol. 33, No. 6, Feb. 2016. [cited by applicant]